Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SABEEN NAJAM

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1124222708
CMS profile
323825
Location
BAYTOWN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,195.86

133 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,195.86 133

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 3; records 101–133 of 133 matching records. This page contains 33 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SABEEN NAJAM

NPI 1124222708 · CMS profile ID 323825

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

BAYTOWN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–133 of 133 matching records. This page contains 33 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124222708?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SABEEN NAJAM, NPI 1124222708, CMS profile ID 323825. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–133 of 133 matching records. This page contains 33 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124222708?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). SABEEN NAJAM, NPI 1124222708, CMS profile ID 323825. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–133 of 133 matching records. This page contains 33 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124222708?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
SABEEN NAJAM, NPI 1124222708, CMS profile ID 323825, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–133 of 133 matching records. This page contains 33 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1124222708?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

133 matching records · $2,195.86 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 133 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–133 of 133.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Horizon Therapeutics plc $18.0004/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797177849 CMS
AbbVie Inc. $19.5404/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795278029 CMS
Lilly USA, LLC $13.5204/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818748857 CMS
Janssen Biotech, Inc. $4.6004/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787877855 CMS
UCB, Inc. $29.5104/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807335111 CMS
AbbVie Inc. $22.1004/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795278023 CMS
GlaxoSmithKline, LLC. $11.5104/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803150535 CMS
Amgen Inc. $25.0303/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825755797 CMS
Janssen Biotech, Inc. $1.2703/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787877897 CMS
Novartis Pharmaceuticals Corporation $20.2003/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813109105 CMS
PFIZER INC. $13.0603/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832622623 CMS
GlaxoSmithKline, LLC. $20.0103/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801670963 CMS
Amgen Inc. $20.2403/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825755813 CMS
GlaxoSmithKline, LLC. $10.8603/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803131807 CMS
Horizon Therapeutics plc $18.4303/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797177847 CMS
PFIZER INC. $18.2103/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832575885 CMS
AbbVie Inc. $21.8503/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795278019 CMS
Amgen Inc. $14.2903/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825755781 CMS
Amgen Inc. $6.9903/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825755809 CMS
E.R. Squibb & Sons, L.L.C. $17.3802/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783554569 CMS
GlaxoSmithKline, LLC. $19.5102/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801670401 CMS
Amgen Inc. $14.0102/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825755777 CMS
AbbVie Inc. $20.8202/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795278013 CMS
UCB, Inc. $29.5102/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807319399 CMS
Mallinckrodt Hospital Products Inc. $22.2802/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845371309 CMS
Novartis Pharmaceuticals Corporation $21.1002/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813109101 CMS
Janssen Biotech, Inc. $16.2901/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787877849 CMS
GlaxoSmithKline, LLC. $19.0601/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803150881 CMS
UCB, Inc. $16.0901/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807308471 CMS
Horizon Therapeutics plc $5.8901/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797177845 CMS
Amgen Inc. $11.6001/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825755773 CMS
PFIZER INC. $19.8901/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832738933 CMS
Radius Health, Inc. $20.8701/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830732515 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,230.89 137
PY2020 $1,938.53 113
PY2021 $2,195.86 133
PY2022 $2,448.29 130
PY2023 $2,723.54 133
PY2024 $2,207.77 108
PY2025 $2,185.17 110

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $556,173.98 95
PY2024 Recipient $104.58 1
PY2024 Principal investigator $190,667.79 25
PY2023 Principal investigator $236,389.90 34
PY2022 Recipient $1,408.00 2
PY2022 Principal investigator $751,145.26 219
PY2021 Principal investigator $825,462.02 135
PY2020 Recipient $1,163.90 3
PY2020 Principal investigator $589,538.84 90
PY2019 Principal investigator $423,512.70 88

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

95 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,400.93 12/16/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT L
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223289714
Principal investigator 1 ARGENX US, INC. $1,613.00 11/20/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144629
Principal investigator 1 Amgen Inc. $5,847.30 11/19/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) No dispute reported 06/30/2026 1246638783
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,736.13 11/18/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT L
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288373
Principal investigator 1 GlaxoSmithKline, LLC. $2,370.60 11/05/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192131914
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,493.48 11/03/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT L
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223287849
Principal investigator 1 ARGENX US, INC. $5,289.00 10/20/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144633
Principal investigator 1 ARGENX US, INC. $576.00 10/20/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144646
Principal investigator 1 Novartis Pharmaceuticals Corporation $46,229.20 10/08/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SL No dispute reported 06/30/2026 1190306199
Principal investigator 1 ARGENX US, INC. $576.00 10/02/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144637
Principal investigator 1 ARGENX US, INC. $576.00 10/02/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144642
Principal investigator 1 ARGENX US, INC. $1,613.00 10/02/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144651
Principal investigator 1 ARGENX US, INC. $3,044.00 10/02/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144654
Principal investigator 1 Novartis Pharmaceuticals Corporation $21,875.60 09/25/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT LLC
A randomized, double-blind, placebo-controlled extension study to assess the long-term safety and tolerability of ianalumab in patients with systemic lupus erythematosus (SIRIUS-SLE extension) No dispute reported 06/30/2026 1190311733
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,986.58 09/18/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223285698
Principal investigator 1 ARGENX US, INC. $1.40 09/03/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144804
Principal investigator 1 ARGENX US, INC. $191.00 09/03/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144812
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,219.78 08/21/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223284511
Principal investigator 1 ARGENX US, INC. $500.00 08/13/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144769
Principal investigator 1 ARGENX US, INC. $4,089.00 08/13/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144772
Principal investigator 1 ARGENX US, INC. $5,782.00 08/13/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144775
Principal investigator 1 ARGENX US, INC. $1,659.00 08/13/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144782
Principal investigator 1 ARGENX US, INC. $1,540.00 08/13/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144785
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 08/07/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192143872
Principal investigator 1 GlaxoSmithKline, LLC. $2,352.60 08/01/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192143867
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,521.18 07/22/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223282942
Principal investigator 1 Eli Lilly and Company $8,100.00 07/14/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT LLC
A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187880153
Principal investigator 1 American Regent $10,954.70 07/07/2025 Non-covered Recipient Entity
Accurant Clinical Management, LLC
TPX-100 No dispute reported 06/30/2026 1232690007
Principal investigator 1 ARGENX US, INC. $429.75 07/01/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144789
Principal investigator 1 ARGENX US, INC. $119.25 07/01/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144794
Principal investigator 1 ARGENX US, INC. $4.20 07/01/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144799
Principal investigator 1 ARGENX US, INC. $56.40 07/01/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144807
Principal investigator 1 UCB SA $32,757.00 06/26/2025 Non-covered Recipient Entity
Accurate Clinical Management, Llc
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246658590
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,416.84 06/24/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223281802
Principal investigator 1 Eli Lilly and Company $110,242.00 06/23/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT LLC
A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187875737
Principal investigator 1 ARGENX US, INC. $77.40 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144657
Principal investigator 1 ARGENX US, INC. $3.15 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144661
Principal investigator 1 ARGENX US, INC. $13.25 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144665
Principal investigator 1 ARGENX US, INC. $143.20 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144669
Principal investigator 1 ARGENX US, INC. $238.75 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144674
Principal investigator 1 ARGENX US, INC. $668.50 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144678
Principal investigator 1 ARGENX US, INC. $286.50 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144681
Principal investigator 1 ARGENX US, INC. $5.60 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144685
Principal investigator 1 ARGENX US, INC. $1.40 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144690
Principal investigator 1 ARGENX US, INC. $2.10 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144693
Principal investigator 1 ARGENX US, INC. $155.25 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144697
Principal investigator 1 ARGENX US, INC. $21.35 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144700
Principal investigator 1 ARGENX US, INC. $85.40 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144704
Principal investigator 1 ARGENX US, INC. $85.40 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144708
Principal investigator 1 ARGENX US, INC. $132.50 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144713
Principal investigator 1 ARGENX US, INC. $214.80 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144718
Principal investigator 1 ARGENX US, INC. $5.25 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144722
Principal investigator 1 ARGENX US, INC. $191.00 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144725
Principal investigator 1 ARGENX US, INC. $477.50 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144728
Principal investigator 1 ARGENX US, INC. $103.50 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144732
Principal investigator 1 ARGENX US, INC. $35.80 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144736
Principal investigator 1 ARGENX US, INC. $1.75 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144740
Principal investigator 1 ARGENX US, INC. $75.20 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144745
Principal investigator 1 ARGENX US, INC. $21.35 06/18/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144751
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,335.53 06/10/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223280988
Principal investigator 1 Amgen Inc. $8,810.00 06/05/2025 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) No dispute reported 06/30/2026 1246638789
Principal investigator 1 GlaxoSmithKline, LLC. $3,186.90 06/04/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192143880
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $808.00 06/04/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243524837
Principal investigator 1 Amgen Inc. $105,678.81 05/22/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246638781
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,290.09 05/20/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223279962
Principal investigator 1 GlaxoSmithKline, LLC. $2,352.60 05/09/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192143876
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,331.58 04/23/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT LLC
INSPIRE LTE study No dispute reported 06/30/2026 1246430620
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $810.00 04/14/2025 Non-covered Recipient Entity
Advarra, Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243527510
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $1,345.00 04/14/2025 Non-covered Recipient Entity
Advarra, Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243527527
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,200.00 04/01/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223277266
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,310.00 04/01/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223277268
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,040.00 04/01/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223277304
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $95.00 03/27/2025 Non-covered Recipient Entity
Advarra, Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243527522
Principal investigator 1 Eli Lilly and Company $4,031.64 03/25/2025 Non-covered Recipient Entity
COLUMBUS CLINICAL RESEARCH INC
A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187878601
Principal investigator 1 ARGENX US, INC. $1,248.00 03/24/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144756
Principal investigator 1 ARGENX US, INC. $2,034.00 03/24/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144759
Principal investigator 1 ARGENX US, INC. $1,800.00 03/24/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144762
Principal investigator 1 ARGENX US, INC. $8,000.00 03/24/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237144766
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $2,482.00 03/24/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243524831
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $810.00 03/17/2025 Non-covered Recipient Entity
Advarra, Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243527504
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $90.00 03/17/2025 Non-covered Recipient Entity
Advarra, Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243527515
Principal investigator 1 Amgen Inc. $33,188.36 03/13/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT-BAYTOWN
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgrens Syndrome With Moderate-to-Severe Systemic Disease Activity No dispute reported 06/30/2026 1246638787
Principal investigator 1 UCB SA $61.84 03/12/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT, LLC
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246658420
Principal investigator 1 GlaxoSmithKline, LLC. $3,168.90 03/07/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192143884
Principal investigator 1 Eli Lilly and Company $9,758.00 02/25/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT LLC
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187874189
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $95.00 02/24/2025 Non-covered Recipient Entity
Advarra, Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243527531
Principal investigator 1 GlaxoSmithKline, LLC. $3,186.90 02/05/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192143860
Principal investigator 1 Amgen Inc. $11,138.97 02/03/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246638785
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,906.14 01/27/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT LLC
INSPIRE LTE study No dispute reported 06/30/2026 1246430622
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $6,000.00 01/17/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243524809
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $3,249.00 01/17/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243524821
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $2,000.00 01/16/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243524814
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $2,716.00 01/16/2025 Non-covered Recipient Entity
Accurate Clinical Management, LLC
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243524827
Principal investigator 1 Eli Lilly and Company $1,738.00 01/09/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT LLC
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187875739
Principal investigator 1 GlaxoSmithKline, LLC. $3,168.90 01/08/2025 Non-covered Recipient Entity
ACCURATE CLINICAL MANAGEMENT LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192143863